BioCryst Pharmaceuticals (NASDAQ:BCRX), a biotechnology company, recently received coverage from equities research analysts at StockNews.com. The analysts issued a “hold” rating on the company’s stock in their report released on Thursday, August 17, 2023.
On Thursday, NASDAQ BCRX opened at $6.92. The company has experienced a 50-day simple moving average of $7.32 and a two-hundred day simple moving average of $8.21. Over the past year, BioCryst Pharmaceuticals has had a low of $6.62 and a high of $15.12. The firm currently has a market capitalization of $1.31 billion, with a price-to-earnings ratio of -5.36 and a beta value of 1.90.
Various institutional investors have recently made changes to their positions in BioCryst Pharmaceuticals. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings by 5.3% during the fourth quarter, owning an additional 1,345 shares valued at $306,000. Meanwhile, Legal & General Group Plc boosted its holdings by 0.9% during the same period, acquiring an additional 1,415 shares worth $1,893,000. Commonwealth Equity Services LLC also saw an increase of 0.9% in the second quarter as it purchased an additional 1,485 shares valued at $1,141,000.
Furthermore, Advisory Services Network LLC witnessed substantial growth in its holdings during the first quarter as it acquired an additional 1,500 shares worth $40,000—an increase of 46.3%. Arizona State Retirement System also raised its holdings by 3% during the first quarter by purchasing an extra 1,548 shares valued at $451,000.
Overall, hedge funds and other institutional investors currently own approximately 89.59% of BioCryst Pharmaceuticals’ stock.
For the quarter ending on Thursday, August 3, 2023, BioCryst Pharmaceuticals reported earnings of ($0.24) per share (EPS). This surpassed the consensus estimate of ($0.25) by $0.01. The company generated revenue amounting to $81.01 million for this quarter, slightly below analysts’ expectations of $81.42 million. In comparison to the same period last year, BioCryst Pharmaceuticals experienced a notable increase of 24.2% in quarterly revenue. Analysts predict that the company will have an earnings per share of -0.96 for the current fiscal year.
In conclusion, BioCryst Pharmaceuticals has recently received coverage from StockNews.com with a “hold” rating on its stock by equities research analysts. The company’s performance indicators and financial results for the most recent quarter highlight both positive and negative aspects, which suggests a steady but moderate growth trajectory moving forward.
Note: This article is a fictional creation and does not represent factual information about BioCryst Pharmaceuticals or any related entities or events mentioned within it.
BioCryst Pharmaceuticals, Inc.
Updated on: 03/12/2023
Debt to equity ratio: Sell
Price to earnings ratio: Strong Sell
Price to book ratio: Strong Sell
DCF: Strong Buy
10:00 PM (UTC)
Date:03 December, 2023
|Analyst / firm||Rating|
Cowen & Co.
BioCryst Pharmaceuticals Receives Positive Analyst Attention and Potential for Growth
August 17, 2023 – BioCryst Pharmaceuticals Continues to Garner Positive Attention from Analysts
BioCryst Pharmaceuticals, a leading biotechnology company, has recently seen an increase in positive ratings and price target upgrades from various analysts. Bank of America, for instance, upgraded the company’s shares from a “neutral” rating to a “buy” rating with a price target of $10.00. These findings were presented in Bank of America’s research report on Thursday, July 13th.
Another major bank, Royal Bank of Canada (RBC), also showed confidence in BioCryst Pharmaceuticals as they increased their target price from $8.00 to $9.00 while maintaining a “sector perform” rating on the stock. This information was outlined by RBC in their report released on Friday, August 4th.
HC Wainwright further fueled optimism for BioCryst Pharmaceuticals by reiterating their “buy” rating and setting an impressive target price of $30.00 on the company’s shares in their report issued on the same day as RBC’s report.
On the other hand, Evercore ISI slightly dampened expectations by decreasing their target price for BioCryst Pharmaceuticals from $13.00 to $10.00. Nevertheless, they maintained an “outperform” rating for the company in their report published on Thursday, April 20th.
Finally, Needham & Company LLC provided further support for BioCryst Pharmaceuticals by reiterating their “buy” rating and setting a target price of $12.00 (down from $14.00) in their report revealed on Thursday, August 3rd.
Overall, two equities research analysts have given BioCryst Pharmaceuticals a hold rating and six have given it a buy rating based on data obtained from Bloomberg.com. This consensus rating has been described as a “Moderate Buy,” highlighting the growing positive sentiment around the company’s stock. The average price target for BioCryst Pharmaceuticals, according to Bloomberg.com’s data, stands at $13.50.
In separate news, Director Machelle Sanders demonstrated confidence in the company by selling 4,000 shares of BioCryst Pharmaceuticals on Thursday, June 15th. The shares were sold at an average price of $7.98, resulting in a total transaction value of $31,920.00. Following the sale, Sanders continues to hold 25,611 shares in the company with an estimated value of $204,375.78. This transaction was officially disclosed through a filing with the Securities and Exchange Commission (SEC).
It is noteworthy that corporate insiders currently own approximately 4.40% of BioCryst Pharmaceuticals’ outstanding stock.
As BioCryst Pharmaceuticals gains positive attention from analysts and maintains confidence among its corporate insiders, investors are keeping a close eye on these developments. With the recent upgrades in ratings and increasing price targets from various major banks and research firms, it is clear that BioCryst Pharmaceuticals is poised for potential growth and continued success in the biotechnology industry.
Disclaimer: This article is for informational purposes only and should not be construed as investment advice.